REGENT PACIFIC GROUP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 HKD | -.--% |
|
-17.54% | -24.19% |
| Sales 2021 | 16.84M 132M 22.99M | Sales 2022 | 35K 274K 47.76K | Capitalization | 24.28M 190M 33.14M |
|---|---|---|---|---|---|
| Net income 2021 | -12M -93.93M -16.38M | Net income 2022 | -36M -282M -49.13M | EV / Sales 2021 | 2.91 x |
| Net Debt 2021 | 1.68M 13.16M 2.29M | Net Debt 2022 | 12.29M 96.21M 16.77M | EV / Sales 2022 | 1,045 x |
| P/E ratio 2021 |
-3.73
x | P/E ratio 2022 |
-0.67
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 40.23% |
More Fundamentals
* Assessed data
More news
Regent Pacific Group Ltd, formerly Endurance RP Ltd is an investment holding company principally engaged in biopharma and investment businesses. The Company operates its business through two segments. The Biopharma segment is engaged in the research, development, manufacture, marketing and sale of pharmaceutical products. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The Company is also engaged in aging research and developing artificial intelligence (AI) models and tool products related to aging research. It offers aging and longevity clocks to the longevity clinics, preventative medicine organizations, health clubs, insurance companies, and aging research institutions.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 575 Stock
- 575 Stock
